Arab Health 2023 will see UltraLinQ Healthcare Solutions launch a new end-to-end patient monitoring concept that revolutionises the way cardiac arrhythmias are diagnosed.
Joining the ABHI UK Pavilion, the company will be showcasing a ground-breaking UltraLinQ Holter Service, enabled by LifeSignals – a complete Wireless Holter Monitoring ECG Analysis and Reporting System, offering wireless ECG recording with clinical-grade wearable biosensors.
Studies have shown 45% of all arrhythmias go undetected during a 24-hour Holter monitoring period used in routine clinical practice. Increasing the monitoring period to seven days can substantially improve the detection of all arrythmias to almost 97%, consequently reducing the risk of stroke.1
The UltraLinQ Holter Service offers a complete, low-cost end-to-end system that enables hospitals and specialist clinics to provide extended Holter services to patients visiting their clinics or remotely at home. Used to assess the patient’s heart rhythm as they go about their normal daily activities, the device can capture data for up to seven days and enables high quality Holter reports to be generated within 36 hours by certified cardiac technicians. Using a pay-per-use model, the system allows hospitals greater flexibility in how they provide care to wider patient base, without overburdening healthcare staff.
The disposable, single-use wearable biosensor device allows patients to be continuously monitored, completely without wires. It can be worn with minimal disruption to the patients’ daily routine, and they can exercise, sleep and shower as normal. The medical device is also designed to be easy to apply without causing discomfort or skin irritation.
Jordan Wittmeier, Head of Commercial & Operations, said: “With thousands of industry players all under one roof over four days, Arab Health is the ideal event to showcase our latest innovation. We look forward to meeting key stakeholders and potential distributors to discuss how our revolutionary end-to-end patient monitoring concept can transform the way cardiac arrhythmias are diagnosed for patients, while enabling hospitals to expand their services, saving both time and costs. This new service will enable improved arrhythmia identification and appropriate management of patients with AF which could save the high cost of long-term care of stroke survivors.”
UltraLinQ is a leading cloud-based platform provider that provides secure, instant access to medical images and data from any location, accelerating patient diagnosis.
LifeSignals, Inc. a US-based medical device company has spent more than decade developing world class biosensors, and cloud-based patient monitoring systems.
The Arab Health Exhibition & Congress is taking place from 30 January – 2 February 2023 at the Dubai Convention and Exhibition Centre. Throughout the exhibition, UltraLinQ will be located on the ABHI UK Pavilion – POD19.
* Turakhia et al (2013). Diagnostic Utility of a Novel Leadless Arrhythmia Monitoring Device. The American journal of Cardiology.
